Escalating R&D woes spur fresh M&A chatter for cash-rich Gilead
Four years after Gilead acquired momelotinib in its $510 million buyout of YM BioSciences, the big — and what appears to be increasingly unlucky — biotech was forced to report that the drug performed poorly in its two Phase III myelofibrosis trials. And the fourth straight pipeline flop quickly spurred fresh speculation that Gilead will soon have to tap into its big cash reserves for a major acquisition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
